These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8127034)

  • 21. Characterization of murine T cell responses to peptides of the variable region of self T cell receptor beta-chains.
    MacNeil D; Fraga E; Singh B
    J Immunol; 1993 Oct; 151(8):4045-54. PubMed ID: 8409384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptides corresponding to CD4-interacting regions of murine MHC class II molecules modulate immune responses of CD4+ T lymphocytes in vitro and in vivo.
    Shen X; Hu B; McPhie P; Wu X; Fox A; Germain RN; König R
    J Immunol; 1996 Jul; 157(1):87-100. PubMed ID: 8683160
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Killer cell inhibitory receptors for MHC class I molecules regulate lysis of melanoma cells mediated by NK cells, gamma delta T cells, and antigen-specific CTL.
    Bakker AB; Phillips JH; Figdor CG; Lanier LL
    J Immunol; 1998 Jun; 160(11):5239-45. PubMed ID: 9605119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells.
    Epel M; Ellenhorn JD; Diamond DJ; Reiter Y
    Cancer Immunol Immunother; 2002 Nov; 51(10):565-73. PubMed ID: 12384808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The T cell receptor gene usage by simian immunodeficiency virus gag-specific cytotoxic T lymphocytes in rhesus monkeys.
    Chen ZW; Shen L; Regan JD; Kou Z; Ghim SH; Letvin NL
    J Immunol; 1996 Feb; 156(4):1469-75. PubMed ID: 8568249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of HLA molecules in the induction of alloimmune responses: clinical significance in the cyclosporine era.
    Thorsby E; Pfeffer P; Leivestad T
    Transplant Proc; 2004 Mar; 36(2 Suppl):16S-21S. PubMed ID: 15041301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The latest developments in synthetic peptides with immunoregulatory activities.
    Zhou CL; Lu R; Lin G; Yao Z
    Peptides; 2011 Feb; 32(2):408-14. PubMed ID: 20979984
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthetic peptides derived from human MHC class I sequences delay allograft rejection in rodents and inhibit cell-mediated cytotoxicity in vivo and in vitro.
    Cuturi MC; Josien R; Douillard P; Giral M; Soulillou JP
    Immunol Rev; 1996 Dec; 154():5-20. PubMed ID: 9034861
    [No Abstract]   [Full Text] [Related]  

  • 29. HLA-derived peptides as novel immunosuppressives.
    Krensky AM; Clayberger C
    Nephrol Dial Transplant; 1997 May; 12(5):865-8. PubMed ID: 9175033
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of T cell receptor antagonism: implications in the treatment of disease.
    Dittel BN
    Curr Mol Med; 2001 Jul; 1(3):339-55. PubMed ID: 11899082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA-derived peptides as novel immunotherapeutics.
    Krensky AM; Clayberger C
    Clin Immunol Immunopathol; 1995 May; 75(2):112-6. PubMed ID: 7704968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design and development of RDP58.
    Iyer S; Lahana R; Buelow R
    Curr Pharm Des; 2002; 8(24):2217-29. PubMed ID: 12369864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunosuppressive peptides and their therapeutic applications.
    Thell K; Hellinger R; Schabbauer G; Gruber CW
    Drug Discov Today; 2014 May; 19(5):645-53. PubMed ID: 24333193
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of novel T cell costimulatory pathways in autoimmunity and transplantation.
    Yamada A; Salama AD; Sayegh MH
    J Am Soc Nephrol; 2002 Feb; 13(2):559-575. PubMed ID: 11805188
    [No Abstract]   [Full Text] [Related]  

  • 35. Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.
    Bakela K; Athanassakis I
    Immunology; 2018 Mar; 153(3):315-324. PubMed ID: 29159903
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants.
    Illigens BM; Yamada A; Anosova N; Dong VM; Sayegh MH; Benichou G
    Eur J Immunol; 2009 Nov; 39(11):3000-9. PubMed ID: 19658090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients.
    Adamashvili I; Kelley RE; Pressly T; McDonald JC
    Rheumatol Int; 2005 Sep; 25(7):491-500. PubMed ID: 15986087
    [No Abstract]   [Full Text] [Related]  

  • 38. T cells in autoimmunity and allograft rejection.
    Krensky AM
    Kidney Int Suppl; 1994 Jan; 44():S50-6. PubMed ID: 8127034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulation by HLA class I-derived peptides.
    Krensky AM; Clayberger C
    Transplant Proc; 1996 Dec; 28(6):3026-8. PubMed ID: 8962174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of allograft tolerance in rats by an HLA class-I-derived peptide and cyclosporine A.
    Nisco S; Vriens P; Hoyt G; Lyu SC; Farfan F; Pouletty P; Krensky AM; Clayberger C
    J Immunol; 1994 Apr; 152(8):3786-92. PubMed ID: 8144948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.